期刊的影响因子--文章列表

期刊文章列表
Yuqiu Xu，Yang Lv，Zhehui Zhu，Yijiao Chen，Peiwen Zhou，Lechi Ye，Wentao Tang，Jianmin Xu（Department of Colorectal Surgery, Zhongshan Hospital, Fudan University）.Precision medicine in the treatment of colorectal cancer with liver metastases[J].Cancer Biology ＆ Medicine,2023,第12期 Mengqian Huang¹，Shenglan Li¹，Parker Li²，Zhuang Kang¹，Botao Zhang¹，Wenbin Li¹（Cancer Center, Beijing Tiantan Hospital, Capital Medical University；Clinical Medicine, Shanghai Jiao Tong University School of Medicine）.Drug clinical trials on high-grade gliomas: challenges and hopes[J].Cancer Biology ＆ Medicine,2023,第12期 Xianchun Gao^1,2，Hui Liu¹，Jun Yu²，Yongzhan Nie^1,2（Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Science and Medicine, Northwest University；State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases,Fourth Military Medical University）.DNA methylation biomarkers for early detection of gastric and colorectal cancers[J].Cancer Biology ＆ Medicine,2023,第12期 Chunhua Song^1,2,3，Hanping Shi^4,5（Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University；Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University；State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University；Department of Gastrointestinal Surgery, Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University；Key Laboratory of Cancer FSMP for State Market Regulation）.Diagnosis of malnutrition in cancer patients[J].Cancer Biology ＆ Medicine,2023,第12期 Jing Qin^1,2,3,4,5，Feng Wei^1,2,3,4,5，Xiubao Ren^1,2,3,4,5,6（National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital；Tianjin’s Clinical Research Center for Cancer；Key Laboratory of Cancer Prevention and Therapy；Key Laboratory of Cancer Immunology and Biotherapy；Department of Immunology,Tianjin Medical University Cancer Institute & Hospital；Department of Biotherapy, Tianjin Medical University Cancer Institute & Hospital）.Neutrophils in the era of single-cell RNA sequencing:functions and targeted therapies in cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Weiji Xie¹，Jiaqian Xu¹，Suying Lu¹，Yizhuo Zhang^1,2（Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center；Young Talents Program of Sun Yat-sen University Cancer Center）.Current therapeutic landscape and resistance mechanisms to larotrectinib[J].Cancer Biology ＆ Medicine,2023,第12期 Xilin Shen，Xiangchun Li（Tianjin Cancer Institute, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer,National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University）.Deep-learning methods for unveiling large-scale single-cell transcriptomes[J].Cancer Biology ＆ Medicine,2023,第12期 Liwei An^1,2，Yi Han²，Shi Jiao¹，Zhaocai Zhou¹（State Key Laboratory of Genetic Engineering, Zhongshan Hospital, School of Life Sciences, Fudan University；Department of Stomatology, Shanghai Tenth People’s Hospital, Department of Biochemistry and Molecular Biology, Tongji University School of Medicine）.Road of no return — loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Haowen Jiang¹，Mohamed Jedoui¹，Jiangbin Ye^1,2,3（Department of Radiation Oncology, Stanford University School of Medicine；Cancer Biology Program, Stanford University School of Medicine；Stanford Cancer Institute, Stanford University School of Medicine）.The Warburg effect drives dedifferentiation through epigenetic reprogramming[J].Cancer Biology ＆ Medicine,2023,第12期 Yuheng Liao¹，Hui Yang^1,2,3（Department of Neurosurgery, Huashan Hospital, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), and Molecular and Cell Biology Lab, Institutes of Biomedical Sciences, Institute for Translational Brain Research, Shanghai Medical College of Fudan University；Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai Clinical Medical Center of Neurosurgery, Neurosurgical Institute of Fudan University, Huashan Hospital, Shanghai Medical College, Fudan University；State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Shanghai Medical College, Fudan University）.Metabolic regulation of innate immunity in cancer immunotherapy[J].Cancer Biology ＆ Medicine,2023,第12期 Shuo Zhang¹，Rui Yang，Yujie Ouyang³，Yang Shen^4,5,6，Lanlin Hu^4,5,7,8，Chuan Xu^4,5,7,8（Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China；Department of Ultrasound in Medicine, Chengdu Wenjiang District People’s Hospital；Acupuncture and Massage College, Chengdu University of Traditional Chinese Medicine；Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China；Sichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China；School of Pharmacy, Macau University of Science and Technology；Yu-Yue Pathology Scientific Research Center；Jinfeng Laboratory）.Cancer stem cells: a target for overcoming therapeutic resistance and relapse[J].Cancer Biology ＆ Medicine,2023,第12期 Canbin Fang¹，Xueqi Fan²，Wanling Lin²，Guojun Zhang^2,3（Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong；Department of Breast Surgery, Yunnan Cancer Hospital and Cancer Institute, The Third Affiliated Hospital of Kunming Medical University；Department of Breast Surgery, Xiang’an Hospital of Xiamen University, Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer, Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine）.Insight into the evolution of breast cancer driven by genetic alterations[J].Cancer Biology ＆ Medicine,2023,第12期 Qin Tang^1,2，Xin Wang^1,2，Haixia Wang^1,2,3，Lin Zhong^1,2，Dongling Zou^1,2,3（Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital；Chongqing Specialized Medical Research Center of Ovarian Cancer；Organoid Transformational Research Center, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital）.Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Lin Ma^1,2，Liufu Deng³，Jianfeng Peng²，Jinming Yu^1,2，Xiangjiao Meng²（Department of Oncology, Renmin Hospital of Wuhan University；Department of Radiation Oncology,Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences；School of Pharmacy, Shanghai Jiao Tong University）.Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?[J].Cancer Biology ＆ Medicine,2023,第12期 Jean-Fran?ois Rossi^1,2，Patrick Frayssinet³，Maksim Matciyak⁴，Nikolai Tupitsyn⁵（Institut du Cancer Avignon-Provence, Sainte Catherine–Department of Hematology-Biotherapy；University of Montpellier, UFR Médecine；HASTIM Inc., Rue de Caulet；Petrovax NPO Pharm；Laboratory of Immunology of Hematopoiesis, N.N.Blokhin Cancer Research Center (RCRC)）.Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Xiaopeng Hao¹，Zefei Jiang²（Department of General Surgery, The First Medical Center of PLA General Hospital；Department of Oncology Medicine, The Fifth Medical Center of PLA General Hospital）.Hot issues in triple-negative breast cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Catalina Amador¹，Wing C.Chan²（Department of Pathology, University of Miami Miller School of Medicine；Department of Pathology,City of Hope National Medical Center）.Nodal peripheral T-cell lymphomas in the new classification systems[J].Cancer Biology ＆ Medicine,2023,第12期 Nanhui Chen，Zengjun Wang²，Ming Chen³，Qi Ma⁴，Yi He⁵，Yujie Wang⁶，Xin Li⁷，Mingxing Qiu，Lei Shi⁹，Shaoxing Zhu¹⁰，Qun Xie¹¹，Xiuheng Liu¹²，Benkang Shi¹³，Guowen Lin¹⁴，Weizhong Yang¹⁵，Yongbin Liao¹⁶，Haibin Zhang¹⁷，Shusheng Wang¹⁸，Jiexian Li¹⁹，Shaogang Wang²⁰，Lijun Dong²¹，Hui Chen²²，Jiaju Lu²³，Yongyi Cheng²⁴，Xiaoping Zhang²⁵，Lulin Ma²⁶，Liqun Zhou²⁷，He Wang²⁸，Shen Li²⁹，Dingwei Ye¹⁴（Department of Urology, Meizhou People’s Hospital；Department of Urology, Jiangsu Province Hospital；Department of Urology, Zhongda Hospital Southeast University；Translational Research Laboratory for Urology, Ningbo First Hospital；Department of Urology, First Affiliated Hospital of Jiaxing；Department of Urology, The First Affiliated Hospital of Xinjiang Medical University；Department of Urology, Baotou Cancer Hospital；Department of Urology, The People’s Hospital of Sichuan Province；Department of Urology, Yantai Yuhuangding Hospital；Department of Urology, Cancer Hospital of The University of Chinese Academy of Sciences；Department of Urology, Zhuhai Hospital Affiliated with Jinan University；Department of Urology,Tongji Hospital, Tongji Medical College, HUST；Department of Urology, Qilu Hospital of Shandong University；Department of Urology, Fudan University Shanghai Cancer Center；Department of Urology, Huizhou Third People’s Hospital；Department of Urology, Jiangmen Central Hospital；Department of Urology, Foshan First People’s Hospital；Department of Urology, Guangzhou Province Traditional Chinese Medical Hospital；Department of Urology,Guangzhou Panyu Central Hospital；Department of Urology, Renmin Hospital of Wuhan University；Department of Urology, Hebei Petro China Central Hospital (China National Petroleum Corporation Central Hospital)；Department of Urology, Harbin Medical University Cancer Hospital；Department of Urology, Shandong Provincial Hospital；Department of Urology, Shaanxi Provincial People’s Hospital；Department of Urology, Union Hospital Tongji Medical College Huazhong University of Science and Technology；Department of Urology, Peking University Third Hospital；Department of Urology, Peking University First Hospital；Department of Urology, Tangdu Hospital；Department of Urology, Shijiazhuang City First Hospital）.Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Feixue Wang¹，Yi Ba^1,2（Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences；Department of GI Medical Oncology, Tianjin Medical University Cancer Institute &Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy）.Treatment strategies for patients with HER2-positive gastric cancer[J].Cancer Biology ＆ Medicine,2023,第12期 Qingxu Liu，Long Li，Wan Qin，Tengfei Chao（Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology）.Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors[J].Cancer Biology ＆ Medicine,2023,第11期 Xiangxiang Gu，Yipan Zhu，Cancan Zhao，Yixin Cao，Jingying Wang，Qiangzhe Zhang，Luyuan Li（State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, and Haihe Laboratory of Cell Ecosystem）.TNFSF15 facilitates the differentiation of CD11b⁺ myeloid cells into vascular pericytes in tumors[J].Cancer Biology ＆ Medicine,2023,第11期 YeleiGuo，Chuan Tong＊，Zhiqiang Wu，Yuting Lu，Yao Wang，Weidong Han（Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital）.Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production[J].Cancer Biology ＆ Medicine,2023,第11期 Yingyan Yu（Department of General Surgery of Ruijin Hospital, Shanghai Institute of Digestive Surgery, and Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine）.Emerging trends in clinical cancer genomic research[J].Cancer Biology ＆ Medicine,2023,第11期 Zengfu Zhang¹，Xiaodong Zhang²，Dawei Chen^1,2（Department of Radiation Oncology, Shandong University Cancer Center；Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences）.Using triple radio-immunotherapy to overcome cancer immunotherapy resistance[J].Cancer Biology ＆ Medicine,2023,第11期 Yinsong Wang（The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University）.Bacterial therapy: a promising strategy for cancer immunotherapy[J].Cancer Biology ＆ Medicine,2023,第11期 Hong Zhang¹，Sen Liu²，Chenghao Ge²，Xiaozhen Liu²，Yang Liu²，Chen Yin²，Yi Li²，Jing An²，Zhongtian Yan²，Xiaoyuan Chen^2,3（Center for Drug Evaluation, National Medical Products Administration；Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University；Office of Clinical Trial Institute, Beijing Tsinghua Changgung Hospital）.Single-arm trials for domestic oncology drug approvals in China[J].Cancer Biology ＆ Medicine,2023,第11期 Chengchen Qian¹，Xiaolong Zou²，Wei Li^1,3，Yinshan Li，Wenqiang Yu⁵（Shanghai Epiprobe Biotechnology Co., Ltd；Department of General Surgery, the First Affiliated Hospital of Harbin Medical University；Shandong Epiprobe Medical Laboratory Co., Ltd；People’s Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University；Shanghai Public Health Clinical Center & Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University）.The outpost against cancer: universal cancer only markers[J].Cancer Biology ＆ Medicine,2023,第11期 Xiaorong Fu^1,2,3，Yi Zhang³，Qing Luo²，Yang Ju³，Guanbin Song²（School of Biology and Engineering, Guizhou Medical University；College of Bioengineering,Chongqing University；Department of Mechanical Science and Engineering, Nagoya University）.Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer[J].Cancer Biology ＆ Medicine,2023,第11期 Liting Chen^1,2,3，Zhijun Ma，Chen Xu^1,2,3，Youbang Xie，Defang Ouyang⁶，Shuhui Song^1,2，Xiao Zhao^3,7,8，Funan Liu^1,2（Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University；Phase I Clinical Trials Center, Ministry of Education, The First Affiliated Hospital of China Medical University；CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology；Department of General Surgery,Panjin People’s Hospital；Department of Hematology and Rheumatology, Qinghai Provincial People’s Hospital；State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau；Center of Materials Science and Optoelectronics Engineering,University of Chinese Academy of Sciences；IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences）.Progress in oncolytic viruses modified with nanomaterials for intravenous application[J].Cancer Biology ＆ Medicine,2023,第11期首页 1 2 3 4 下一页尾页共有4页，转到页

期刊文章列表